jRCT2080221706未知1 期
Phase I trial of YHI-1003 Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 18
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open-label, Multicenter Trial
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1)Patients were previously diagnosed with multiple myeloma
- •(2)Patients must have relapsed after their last dose of bortezomib-based therapy
- •(3)Patients must have received 1 to 4-myeloma therapies
- •(4)ECOG performance status (PS) :0-2
排除标准
- •(1)Patients with uncontrolled intercurrent illness
- •(2)Female patients who are pregnant or lactating
- •(3)Patients with non-secretory multiple myeloma
结局指标
主要结局
-
safety CTCAE v3.0
次要结局
未报告次要终点
研究者
相似试验
招募中
2 期
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom*s Macroglobulinemia: A multicenter Trial of the European Myeloma NetworkWaldenstroms Macroglobulinemiaimmunocytomalymphoplasmacytic lymphoma10018865NL-OMON30654Academisch Medisch Centrum5
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia: A multicenter Trial of the European Myeloma Network - protocole BDRMacroglobulinémie de Waldenström au moment de l’initiation du traitement de 1e ligne.EUCTR2006-003563-31-FRCentre Hospitalier de Lens61
进行中（未招募）
不适用
Phase II Study of combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom?s Macroglobulinemia: A multicenter Trial of the European Myeloma Network - NDWaldenstrom macroglobulinemiaMedDRA version: 9.1Level: LLTClassification code 10047714Term: Von Waldenstrom macroglobulinaemiaEUCTR2006-003563-31-ITE.M.N. - EUROPEAN MYELOMA NETWORK61
进行中（未招募）
不适用
Estudio de fase II con Bortezomib, Dexametasona y Rituximab en combinación, en pacientes con Macroglobulinemia de Waldenström (MW) sin tratamiento previo (Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia) - protocol BDRMacroglobulinemia de Waldenström (MW) [Waldenstrom’s Macroglobulinemia]MedDRA version: 8.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaEUCTR2006-003563-31-ESRed Europea de Mieloma (European Myeloma Network)90
招募中
2 期
A Phase II trial of bortezomib and dexamethasone in renally-impaired patients with untreated multiple myeloma.ntreated Multiple Myeloma patients with renal impairment.Untreated Multiple Myeloma patients with renal impairment.Cancer - MyelomaBlood - Haematological diseasesRenal and Urogenital - Other renal and urogenital disordersACTRN12611000605998Prof. Andrew Spencer28